BACKGROUND: Myasthenia gravis (MG) is an autoimmune disorder of neuromuscular transmission. The majority of patients show abnormal thymic histology. SETTING: The study was performed at the Myasthenia Gravis Centre, Karolinska University Hospital, and at the Immunological Research Laboratory, Centre for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden. PATIENTS AND METHODS: Information was collected retrospectively from 1956 and prospectively from 1975 on clinical data, concomitant diseases, concentration of serum acetylcholine receptor antibodies (AChR-abs), immunosuppressive treatment (IS) and response to it, in 537 patients of whom 326 were thymectomised. Follow-up time was 1.5-50 years. RESULTS: Age at onset of MG increased from a median age of 24 years before 1975 to a median age of 61 years after 2000. Thymoma was found in 65, hyperplasia (HPL) in 185 and a normal thymus in 76 patients. The trans-sternal surgical approach for thymectomy was used in 255 patients (78%). In five patients with thymoma, MG appeared after thymectomy. Of 537 patients, 466 (87%) had circulating AChR-abs. IS was given to 300 (56%) patients, mostly those with thymoma (85%). In total, 441 patients (82%) showed an improvement. One-third of patients with HPL, a quarter of those with thymoma, one-fifth of those with a normal thymus and one-seventh of those not operated on went into remission. CONCLUSION: The prognosis for the majority of patients with MG is favourable, irrespective of thymic histology. The cause may be the use of immunomodulating therapy.
BACKGROUND:Myasthenia gravis (MG) is an autoimmune disorder of neuromuscular transmission. The majority of patients show abnormal thymic histology. SETTING: The study was performed at the Myasthenia Gravis Centre, Karolinska University Hospital, and at the Immunological Research Laboratory, Centre for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden. PATIENTS AND METHODS: Information was collected retrospectively from 1956 and prospectively from 1975 on clinical data, concomitant diseases, concentration of serum acetylcholine receptor antibodies (AChR-abs), immunosuppressive treatment (IS) and response to it, in 537 patients of whom 326 were thymectomised. Follow-up time was 1.5-50 years. RESULTS: Age at onset of MG increased from a median age of 24 years before 1975 to a median age of 61 years after 2000. Thymoma was found in 65, hyperplasia (HPL) in 185 and a normal thymus in 76 patients. The trans-sternal surgical approach for thymectomy was used in 255 patients (78%). In five patients with thymoma, MG appeared after thymectomy. Of 537 patients, 466 (87%) had circulating AChR-abs. IS was given to 300 (56%) patients, mostly those with thymoma (85%). In total, 441 patients (82%) showed an improvement. One-third of patients with HPL, a quarter of those with thymoma, one-fifth of those with a normal thymus and one-seventh of those not operated on went into remission. CONCLUSION: The prognosis for the majority of patients with MGis favourable, irrespective of thymic histology. The cause may be the use of immunomodulating therapy.
Authors: A Jaretzki; R J Barohn; R M Ernstoff; H J Kaminski; J C Keesey; A S Penn; D B Sanders Journal: Neurology Date: 2000-07-12 Impact factor: 9.910
Authors: M Jallouli; D Saadoun; B Eymard; G Leroux; J Haroche; D Le Thi Huong; C De Gennes; C Chapelon; O Benveniste; B Wechsler; P Cacoub; Z Amoura; J C Piette; N Costedoat-Chalumeau Journal: J Neurol Date: 2011-12-08 Impact factor: 4.849
Authors: John D Rioux; Philippe Goyette; Timothy J Vyse; Lennart Hammarström; Michelle M A Fernando; Todd Green; Philip L De Jager; Sylvain Foisy; Joanne Wang; Paul I W de Bakker; Stephen Leslie; Gilean McVean; Leonid Padyukov; Lars Alfredsson; Vito Annese; David A Hafler; Qiang Pan-Hammarström; Ritva Matell; Stephen J Sawcer; Alastair D Compston; Bruce A C Cree; Daniel B Mirel; Mark J Daly; Tim W Behrens; Lars Klareskog; Peter K Gregersen; Jorge R Oksenberg; Stephen L Hauser Journal: Proc Natl Acad Sci U S A Date: 2009-10-21 Impact factor: 11.205
Authors: Anne Taraldsen Heldal; Geir Egil Eide; Fredrik Romi; Jone Furlund Owe; Nils Erik Gilhus Journal: PLoS One Date: 2014-12-02 Impact factor: 3.240